Activity of colistin against heteroresistant Acinetobacter baumannii and emergence of resistance in an in vitro Pharmacokinetic/Pharmacodynamic model

被引:119
作者
Tan, Chun-Hong [1 ]
Li, Jian [1 ]
Nation, Roger L. [1 ]
机构
[1] Monash Univ, Victorian Coll Pharm, Facil Antiinfect Drug Dev & Innovat, Parkville, Vic 3052, Australia
关键词
D O I
10.1128/AAC.01571-06
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Three clinically relevant intermittent regimens, and a continuous infusion, of colistin were simulated in an in vitro pharmacokinetic/pharmacodynamic model against two colistin-heteroresistant strains of Acinetobacter baumannii. Extensive initial killing was followed by regrowth as early as 6 h later; bacterial density in the 24-to 72-h period was within 1 log(10) CFU/ml of growth control. Population analysis profiles revealed extensive emergence of resistant subpopulations regardless of the collistin regimen.
引用
收藏
页码:3413 / 3415
页数:3
相关论文
共 26 条
[1]   Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa [J].
Bergen, Phillip J. ;
Li, Jian ;
Rayner, Craig R. ;
Nation, Roger L. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (06) :1953-1958
[2]   Colistin: The revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections [J].
Falagas, ME ;
Kasiakou, SK .
CLINICAL INFECTIOUS DISEASES, 2005, 40 (09) :1333-1341
[3]   Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004) [J].
Gales, AC ;
Jones, RN ;
Sader, HS .
CLINICAL MICROBIOLOGY AND INFECTION, 2006, 12 (04) :315-321
[4]   Overview of nosocomial infections caused by gram-negative bacilli [J].
Gaynes, R ;
Edwards, JR .
CLINICAL INFECTIOUS DISEASES, 2005, 41 (06) :848-854
[5]   NEW INVITRO MODEL TO STUDY EFFECT OF ANTIBIOTIC CONCENTRATION AND RATE OF ELIMINATION ON ANTIBACTERIAL ACTIVITY [J].
GRASSO, S ;
MEINARDI, G ;
DECARNERI, I ;
TAMASSIA, V .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1978, 13 (04) :570-576
[6]  
*INF DIS SOC AM, 2004, BAD BUGS NO DRUGS
[7]   Multidrug-resistant Acinetobacter infections:: An emerging challenge to clinicians [J].
Jain, R ;
Danziger, LH .
ANNALS OF PHARMACOTHERAPY, 2004, 38 (09) :1449-1459
[8]   Cure of multidrug-resistant Acinetobacter baumannii fixation device-related orthopedic infections in two patients with intravenous colistin [J].
Kasiakou, SK ;
Fragoulis, K ;
Tzagarakis, G ;
Mistidis, P ;
Kapaskelis, A ;
Falagas, ME .
MICROBIAL DRUG RESISTANCE, 2005, 11 (03) :287-289
[9]   Successful treatment of multidrug-resistant Acinetobacter baumannii central nervous system infections with colistin [J].
Katragkou, A ;
Roilides, E .
JOURNAL OF CLINICAL MICROBIOLOGY, 2005, 43 (09) :4916-4917
[10]   Pharmacokinetics of colistin methanesulfonate and colistin in a critically ill patient receiving continuous venovenous hemodiafiltration [J].
Li, J ;
Rayner, CR ;
Nation, RL ;
Deans, R ;
Boots, R ;
Widdecombe, N ;
Douglas, A ;
Lipman, J .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (11) :4814-4815